Summary
12.62 -0.63(-4.75%)10/11/2024
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.75 | 25.42 | 39.59 | 376.00 | 209.17 | 0.00 | 0.00 | 153.25 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.62 | |
| Open | 11.50 | |
| High | 12.79 | |
| Low | 9.66 | |
| Volume | 5,152,959 | |
| Change | -0.63 | |
| Change % | -4.75 | |
| Avg Volume (20 Days) | 2,510,053 | |
| Volume/Avg Volume (20 Days) Ratio | 2.05 | |
| 52 Week Range | 0.00 - 0.00 | |
| Price vs 52 Week High | inf% | |
| Price vs 52 Week Low | inf% | |
| Range | 13.33 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 827 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
10/11 08:30 EST - globenewswire.com
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 are being presented at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 are being presented at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.
10/10 17:14 EST - globenewswire.com
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.
10/07 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit in New York, NY on October 8, 2024 and the JonesResearch Virtual Radiopharma Day on October 29, 2024.
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit in New York, NY on October 8, 2024 and the JonesResearch Virtual Radiopharma Day on October 29, 2024.
10/02 15:11 EST - seekingalpha.com
Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept
Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma.
Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept
Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma.
10/02 12:10 EST - gurufocus.com
Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2
Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63.
Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2
Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63.
09/30 07:00 EST - globenewswire.com
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company's other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM.
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company's other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM.
09/05 07:00 EST - globenewswire.com
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma.
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma.
08/28 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
08/13 10:40 EST - zacks.com
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
08/12 16:05 EST - globenewswire.com
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024.
07/30 07:00 EST - globenewswire.com
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.
07/25 06:15 EST - investorplace.com
3 Outperforming Stocks Surpassing Even Nvidia This Year
Nvidia (NASDAQ: NVDA ) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%.
3 Outperforming Stocks Surpassing Even Nvidia This Year
Nvidia (NASDAQ: NVDA ) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%.
07/22 07:00 EST - globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
07/16 10:56 EST - zacks.com
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 80.3% in Perspective Therapeutics (CATX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 80.3% in Perspective Therapeutics (CATX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
06/12 07:00 EST - globenewswire.com
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th.
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th.
06/11 07:00 EST - globenewswire.com
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-adjusted basis under the existing trading symbol “CATX” and new CUSIP number 46489V302.
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-adjusted basis under the existing trading symbol “CATX” and new CUSIP number 46489V302.
06/10 16:10 EST - globenewswire.com
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company's alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June 8-11, 2024, in Toronto Canada.
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company's alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June 8-11, 2024, in Toronto Canada.
05/24 08:01 EST - globenewswire.com
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock at a price of $1.509 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective.
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock at a price of $1.509 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective.
05/20 09:45 EST - insidertrades.com
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys.
05/20 07:00 EST - globenewswire.com
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company's sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging (“SNMMI”) Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Company notes that results based on investigator-initiated use of its assets are also being presented.
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company's sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging (“SNMMI”) Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Company notes that results based on investigator-initiated use of its assets are also being presented.